Protocol for the Examination of Specimens From Patients With Carcinoma of the Adrenal Gland

Version: 4.3.0.0
Protocol Posting Date: December 2022
CAP Laboratory Accreditation Program Protocol Required Use Date: September 2023

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Adrenalectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical carcinoma</td>
<td>For all age groups with a diagnosis of adrenal cortical carcinoma. This protocol is not designed for adrenal cortical tumors (neoplasms) of uncertain malignant potential.</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy (includes needle and incisional biopsies)</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (e.g., following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumors of the adrenal medulla (e.g., pheochromocytoma)</td>
</tr>
<tr>
<td>Adrenal cortical tumors (neoplasms) of uncertain malignant potential</td>
</tr>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
</tbody>
</table>

Authors
Ozgur Mete, MD*; Sylvia L. Asa, MD, PhD; Jessica L. Davis, MD; Lori Erickson, MD; Thomas J. Giordano, MD, PhD; Lester D.R. Thompson, MD; Arthur Tischler, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined."
- Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- Optional data elements are identified with "+" and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including "Cannot be determined" if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.
Summary of Changes
v 4.3.0.0

- WHO 5th edition updates
- Updated Sites Involved by Direct Tumor Extension
- Lymphovascular update to Lymphatic and / or Vascular Invasion
- Updated pTNM Classification
- Updated Special Studies
Reporting Template
Protocol Posting Date: December 2022
Select a single response unless otherwise indicated.

CASE SUMMARY: (ADRENAL GLAND)
Standard(s): AJCC-UICC 8
# This protocol applies to adrenal cortical carcinomas in all age groups.

CLINICAL

+Patient Age Group
   ___ Adult (older than 18 years)
   ___ Pediatric (18 years old or younger)

+Clinical History (specify): ________________

+Functional Status (Notes A,B) (select all that apply)
   ___ Urinary 17-ketosteroids increased (10 mg / g creatinine / 24 hours)
   ___ Cushing syndrome
   ___ Conn syndrome
   ___ Virilization
   ___ Feminization
   ___ Weight loss
   ___ Other (specify): ________________

SPECIMEN

Procedure
   ___ Adrenalectomy, total
   ___ Adrenalectomy, partial
   ___ Other (specify): ________________
   ___ Not specified

Specimen Laterality
   ___ Right
   ___ Left
   ___ Bilateral
   ___ Other (specify): ________________
   ___ Not specified

TUMOR

Histologic Subtype (Notes C,D)
   ___ Conventional adrenal cortical carcinoma
   ___ Oncocytic adrenal cortical carcinoma
   ___ Myxoid adrenal cortical carcinoma
   ___ Sarcomatoid adrenal cortical carcinoma
Other histologic subtype not listed (specify): ____________________
Carcinoma, subtype cannot be determined: ____________________

+Histologic Subtype Comment: ____________________

Mitotic Tumor Grade (required for adult patients only) (Notes C,D)
Not applicable
Low grade (less than or equal to 20 mitoses per 10 mm2)
High grade (greater than 20 mitoses per 10 mm2)
# Generally due to core needle biopsy, with insufficient viable tumor to count 10 mm2.
Cannot be assessed (explain)#: ____________________

Tumor Size (Notes E,F)
Greatest dimension in Centimeters (cm): ____________ cm
Additional Dimension in Centimeters (cm): ____ x ____ cm
Cannot be determined (explain): ____________________

Adrenal Gland Weight (Note G)
Specify weight (g): _________________ g
Other (specify): _________________
Cannot be determined: ____________________

Site(s) Involved by Direct Tumor Extension (select all that apply)
Confined to adrenal cortex without invasion into or through the adrenal capsule (if present)
Invades into or through the adrenal capsule, with no peri-adrenal adipose tissue invasion
Kidney
Pancreas
Liver
Spleen
Diaphragm
Stomach
Peri-adrenal adipose tissue
Large blood vessels
Other adjacent organs and structures (specify): ____________________
Cannot be determined: ____________________
Not applicable (no evidence of primary tumor)

Lymphatic and / or Vascular Invasion (Note H) (select all that apply)
Not identified
Large vessel invasion, renal vein (including when identified clinically or grossly)
Large vessel invasion, vena cava (including when identified clinically or grossly)
Large vessel invasion, not otherwise specified
Microscopic angioinvasion
Lymphatic invasion
Cannot be determined: ____________________

+Tumor Description (select all that apply)
Hemorrhagic
___ Necrotic
___ Other (specify): __________________

+Tumor Comment: __________________

MARGINS

Margin Status
___ All margins negative for carcinoma

Closest Margin(s) to Carcinoma
___ Specify closest margin(s): __________________
___ Cannot be determined (explain): __________________

+Distance from Carcinoma to Closest Margin
Specify in Millimeters (mm)
___ Exact distance: ______________ mm
___ At least: ______________ mm
___ Less than 1 mm
___ Other (specify): __________________
___ Cannot be determined (explain): __________________
___ Carcinoma present at margin

Margin(s) Involved by Carcinoma
___ Specify involved margin(s): __________________
___ Cannot be determined (explain): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

+Margin Comment: __________________

REGIONAL LYMPH NODES (Note I)

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
___ All regional lymph nodes negative for tumor
___ Tumor present in regional lymph node(s)

Number of Lymph Nodes with Tumor
___ Exact number (specify): __________________
___ At least (specify): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

+Extranodal Extension
___ Not identified
___ Present
___ Cannot be determined: __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________
Number of Lymph Nodes Examined
   ___ Exact number (specify): ____________________
   ___ At least (specify): ____________________
   ___ Other (specify): ____________________
   ___ Cannot be determined (explain): ____________________

Regional Lymph Node Comment: ____________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable (select all that apply)
   ___ Not applicable
   ___ Liver: ____________________
   ___ Lung: ____________________
   ___ Other (specify): ____________________
   ___ Cannot be determined: ____________________

pTNM CLASSIFICATION (AJCC 8th Edition) (Note J)

Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

Modified Classification (required only if applicable) (select all that apply)
   ___ Not applicable
   ___ y (post-neoadjuvant therapy)
   ___ r (recurrence)

pT Category

There is no category of carcinoma in situ (pTis) relative to carcinomas of the adrenal gland.
   ___ pT not assigned (cannot be determined based on available pathological information)
   ___ pT0: No evidence of primary tumor
   ___ pT1: Tumor less than or equal to 5 cm in greatest dimension, no extra-adrenal invasion
   ___ pT2: Tumor greater than 5 cm, no extra-adrenal invasion
   ___ pT3: Tumor of any size with local invasion, but not invading adjacent organs
   ___ pT4: Tumor of any size with invasion of adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava)

T Suffix (required only if applicable)
   ___ Not applicable
   ___ (m) multiple primary synchronous tumors in a single organ

pN Category (Note J)

   ___ pN not assigned (no nodes submitted or found)
   ___ pN not assigned (cannot be determined based on available pathological information)
   ___ pN0: No regional lymph node metastasis
   ___ pN1: Metastasis in regional lymph node(s)
pM Category (required only if confirmed pathologically) (Note K)
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis

ADDITIONAL FINDINGS

+ Additional Findings (select all that apply)
___ None identified
___ Hemorrhage
___ Cystic change
___ Calcifications
___ Other (specify): _________________

SPECIAL STUDIES (Note L)

Ki-67 Labeling Index
___ Specify percentage: _________________ %
___ Other (specify): _________________
___ Pending

Biomarkers Confirming Adrenal Cortical Origin# (select positive biomarker(s)) (select all that apply)
# Required for all non-functional adrenal tumors. SF1 (steroidogenic factor-1) is the most reliable biomarker. The remaining biomarkers listed are non-specific.
___ Not applicable
___ SF1 (steroidogenic factor-1)
___ Melan-A
___ Calretinin
___ Alpha-inhibin
___ Synaptophysin
___ Other (specify): _________________

+p53
___ Overexpression
___ Global loss
___ Wild-type staining (variable)
___ Other (specify): _________________

+Beta-catenin
___ Nuclear and cytoplasmic reactivity
___ Membranous
___ Other (specify): _________________

+Reticulin Stain Results (specify type(s) and result(s)): _________________

+Other Ancillary Study Findings (specify type(s) and result(s)): _________________
COMMENTS

Comment(s): _________________
Explanatory Notes

A. Relevant History
Endocrine manifestations, such as hypertension, change in body habitus, feminization, or virilism, are important, as is the knowledge of whether the patient suffers from an adrenal-related disease or syndrome (e.g., Cushing disease, Conn syndrome).

Also of import are family history, previous surgery for adrenal tumors (both benign and malignant) or other endocrine organs, other tumors that may metastasize to the adrenal gland, and endocrine or other therapies. In addition, while the majority of adrenal cortical carcinomas occur sporadically, occasionally adrenal cortical carcinoma may be associated with hereditary cancer syndromes.1,2 Such hereditary cancer syndromes include but not limited to Li-Fraumeni syndrome or SBLA (sarcoma; breast and brain tumors; leukemia, laryngeal carcinoma, and lung cancer; and adrenal cortical carcinoma) syndrome,2 Beckwith-Wiedemann syndrome,1 and Lynch syndrome.3,4

References

B. Endocrine Status
Laboratory findings are important in the evaluation of an adrenal mass. Tumors that are functional, i.e., secrete cortisol, aldosterone, or sex hormones, tend to be discovered at an earlier stage than nonfunctional tumors. Virilizing tumors are more frequently identified as carcinomas than adenomas in adult age groups.1 Nonfunctional tumors come to attention due to mass effect and are usually larger. Adrenal cortical neoplasms that secrete glucocorticoids can also be diagnosed by pathologists by checking the status of the non-tumorous adrenal cortex. In the absence of exogenous cortisol administration, the presence of atrophy in the non-tumorous cortex should prompt the attention of the pathologist to the possibility of glucocorticoid-secreting adrenal cortical neoplasm.1,2,3 This issue is of clinical significance, especially in patients with subclinical Cushing syndrome as affected patients may develop Addisonian crisis if postoperative cortisol replacement is not considered.1,2,3 Therefore, the thickness of the nontumorous cortex should be checked in all adrenalectomy specimens.1 In addition, careful evaluation of the non-tumorous cortex may help to identify underlying pathologies like PPNAD (primary pigmented nodular adrenal cortical disease).1,4 Evidence also suggests that functional adrenal cortical carcinomas are biologically more aggressive than non-functional carcinomas.1,5

References


C. Histologic Subtypes

The following histologic classification of adrenal tumors is from the 5th edition of the World Health Organization (WHO) classification of tumors of the adrenal gland. Thus, this protocol applies only to adrenal cortical carcinoma and its subtypes (conventional, oncocytic, myxoid, and sarcomatoid) and does not apply to other adrenal tumors.

References


D. Mitotic Tumor Grade

Adrenal cortical carcinomas are not usually graded on histologic grounds. Severe nuclear atypia, high mitotic count, vascular invasion, tumor necrosis, and other microscopic features may, in combination, support a diagnosis of adrenal cortical carcinoma using several multifactorial scoring systems (Tables 1-6). When several histologic features are present together (e.g., necrosis, vascular invasion, increased mitotic activity, and atypical mitoses), the risk of distant metastases is increased. In some studies, specific combinations of features, such as mitotic rate of >5 per 10mm$^2$ [50 high-power fields; 50 HPF] along with atypical mitosis and venous invasion (vascular invasion), have been found to correlate with metastasis or recurrence of adult adrenal cortical carcinomas.

Mitotic index has been identified as a prognostic factor that is independently predictive of behavior, with low- and high-grade categories applied based on ≤20 mitoses per 10mm$^2$ (50 HPF) and >20 mitoses per 10mm$^2$ (50 HPF). While the concept of mitotic tumor grade is often used in adult adrenal cortical carcinomas, the optimal cut-off for pediatric adrenal cortical cancers remains to be validated in large clinical series. Nevertheless, documentation of this finding in pediatric age group tumors is recommended.

Other scoring systems are suggested that are able to predict metastatic potential, with 3 x mitotic rate (>5 mitoses per 10mm$^2$)+ 5 x presence of necrosis + numeric value of Ki-67 proliferation index in the most proliferative areas (using an automated image analysis algorithm) (Table 5). Further, Ki-67 has been found to show a superior performance of estimating proliferative rate compared to mitotic count in hematoxylin-eosin sections, suggested to be a better prognostic indicator in overall patient survival. Finally, a reticulin algorithm (Table 3) has been recommended to assess change in reticulin pattern of staining based on necrosis, high mitotic rate (>5 mitoses per 10mm$^2$ [50 HPF]), and vascular invasion.
The criteria used in adults to separate benign from malignant cortical tumors are not entirely applicable to adrenocortical tumors in pediatric age groups. Further, pediatric adrenocortical neoplasms showing histologic features worrisome for malignancy in adults (e.g., capsular invasion, vascular invasion, increased mitotic activity, atypical mitoses, necrosis) may not be predictive of biologic behavior; such a pediatric adrenocortical neoplasm exhibiting such histologic features may have a clinically benign course. A number of classification schemes attempting to separate benign from malignant pediatric adrenocortical tumors have been proposed. One of these studies is based on the presence (carcinoma) or absence (adenoma) of 4 histologic features (modified Weiss system) including high nuclear grade, necrosis, mitotic rate greater than 5 per 10mm² (50 HPF), and atypical mitoses; another study found that tumor weight was the only reliable predictor of behavior, with tumors weighing over 500 g being malignant; and another study correlated tumor volume of greater than 200 cm³ and weight greater than 80 g associated with an adverse outcome. Subsequent to these studies, Wieneke et al. (Table 6) proposed classifying pediatric adrenocortical neoplasms based on a series of 9 criteria including tumor weight greater than 400 g, tumor size greater than 10.5 cm, extension into periadrenal soft tissues and/or adjacent organs, invasion into the vena cava, venous invasion, capsular invasion, presence of tumor necrosis, mitotic rate greater than 15 per 4mm² (20 HPF), and the presence of atypical mitoses; based on this study, the presence of up to 2 of these criteria was associated with a benign outcome, 3 criteria were considered indeterminate for malignancy, and 4 or more criteria were associated with malignant behavior. A recent series also underscored that the Wieneke multiparameter scoring system can accurately predict the clinical course of childhood adrenal cortical tumors.

Traditionally, the Lin-Weiss-Bisceglia criteria (Table 4) are applied to oncocytic adrenocortical tumors. The identification of one of the three major criteria (vascular invasion, atypical mitosis, and mitotic activity greater than 5 per 10mm² [50 HPF]) supports the diagnosis of oncocytic adrenocortical carcinoma, whereas the presence of any minor criteria (large tumor size greater than 10 cm and/or tumor weight greater than 200 gram, necrosis, capsular invasion and sinusoidal invasion) warrants the diagnosis of an oncocytic adrenocortical tumor of uncertain malignant potential. The diagnosis of an oncocytic adrenocortical adenoma requires absence of all major and minor criteria.

The 5th edition of the WHO classification of adrenal cortical carcinomas has expanded on the use of multiparameter algorithms (Tables 1-6). Accordingly, pediatric adrenal cortical carcinoma is rendered using the Wieneke criteria score ≥4 (Table 6). Conventional adrenal cortical carcinomas in adults can be rendered when an adrenal cortical neoplasm fulfills one of the following: Weiss score ≥3, Modified Weiss score ≥3, Helsinki score >8.5, and Reticulin algorithm (Tables 1-4). Oncocytic adrenal cortical carcinomas can be diagnosed using one of the following: Lin-Weiss-Bisceglia (any major criterion), Helsinki score >8.5, and Reticulin algorithm (Tables 3-5). Myxoid adrenal cortical carcinomas are rare and can be assessed using the Weiss, Modified Weiss, and Helsinki scoring systems, as well as the Reticulin algorithm (Tables 1, 2, 3, and 5).

**Table 1. Weiss Scoring System**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Fuhrman nuclear grade (III or IV)</td>
<td>1</td>
</tr>
<tr>
<td>Mitotic count &gt;5 per 10mm² (50 high-power fields)</td>
<td>1</td>
</tr>
<tr>
<td>Atypical mitosis</td>
<td>1</td>
</tr>
<tr>
<td>Necrosis</td>
<td>1</td>
</tr>
<tr>
<td>Diffuse architecture &gt;30% of tumor volume</td>
<td>1</td>
</tr>
<tr>
<td>Clear cells ≤25% of the tumor volume</td>
<td>1</td>
</tr>
<tr>
<td>Capsular invasion</td>
<td>1</td>
</tr>
<tr>
<td>Venous invasion</td>
<td>1</td>
</tr>
<tr>
<td>Sinusoidal (lymphatic) invasion</td>
<td>1</td>
</tr>
<tr>
<td>Total score</td>
<td>9</td>
</tr>
</tbody>
</table>

*A score of ≥3 indicates a diagnosis of adrenal cortical carcinoma*

### Table 2. Modified Weiss System

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitotic count &gt;5 per 10mm² (50 high-power fields)</td>
<td>2</td>
</tr>
<tr>
<td>Clear cells in ≤25%</td>
<td>2</td>
</tr>
<tr>
<td>Atypical mitosis</td>
<td>1</td>
</tr>
<tr>
<td>Necrosis</td>
<td>1</td>
</tr>
<tr>
<td>Capsular invasion</td>
<td>1</td>
</tr>
<tr>
<td>Total score</td>
<td>7</td>
</tr>
</tbody>
</table>

*A score of ≥3 indicates a diagnosis of adrenal cortical carcinoma*

### Table 3. Reticulin Algorithm

Criteria

- Altered reticulin framework in association with one of the following features indicates malignancy:
  - Mitotic count >5 per 10mm² (50 high-power fields)
  - Tumor necrosis
  - Vascular invasion (angioinvasion)

### Table 4. Lin-Weiss-Bisceglia Criteria for Oncocytic Adrenal Cortical Neoplasms*

<table>
<thead>
<tr>
<th>Major criteria</th>
<th>Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitoses &gt;5 per 10mm² (50 high-power fields)</td>
<td>Large size (&gt;10 cm and/or &gt;200 g)</td>
</tr>
<tr>
<td>Atypical mitosis</td>
<td>Necrosis</td>
</tr>
<tr>
<td>Venous invasion</td>
<td>Capsular invasion</td>
</tr>
</tbody>
</table>

*Oncocytic adrenal cortical carcinoma: at least one major criterion; Oncocytic adrenal cortical neoplasm of uncertain malignant potential: at least one minor criterion; Oncocytic adrenal cortical adenoma: Absence of major and minor criteria.*

### Table 5. Helsinki Scoring System

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitoses &gt;5 per 10mm² (50 high-power fields)</td>
<td>3</td>
</tr>
<tr>
<td>Necrosis</td>
<td>5</td>
</tr>
<tr>
<td>Ki-67 proliferation index (%)*</td>
<td></td>
</tr>
<tr>
<td>Score 0 to 8.5: Adrenal cortical adenoma</td>
<td></td>
</tr>
<tr>
<td>Score &gt;8.5: Adrenal cortical carcinoma</td>
<td></td>
</tr>
<tr>
<td>Score &gt;17: Adverse prognosis</td>
<td></td>
</tr>
</tbody>
</table>

*Numeric value of the Ki-67 index from the highest proliferative area*

*The original study used an automated image analysis for the assessment of the Ki-67 proliferation index*

### Table 6. Wieneke Criteria for Pediatric Adrenal Cortical Neoplasms

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor weight &gt;400 g</td>
<td>1</td>
</tr>
<tr>
<td>Tumor size &gt;10.5 cm</td>
<td>1</td>
</tr>
<tr>
<td>Extension into periadrenal soft tissue or adjacent organs</td>
<td>1</td>
</tr>
<tr>
<td>Invasion into vena cava</td>
<td>1</td>
</tr>
</tbody>
</table>
Invasion into vena cava 1
Capsular invasion 1
Presence of tumor necrosis 1
Mitoses >15 per 4 mm² (20 high-power fields²) 1
Presence of atypical mitosis 1
Total score
Malignant/poor outcome: score ≥4 poor clinical outcome
Uncertain malignant potential: score 3
Benign behavior: score ≤2

References


E. Adrenal Incidentalomas

With the technical advancement and availability of radiographic imaging, many asymptomatic adrenal neoplasms are coming to clinical attention at much smaller limits. Such asymptomatic neoplasms are referred to as "adrenal incidentalomas." Adrenal incidentalomas can present clinical dilemmas to the treating physician. A consensus statement on how to manage adrenal incidentalomas was proposed in 2002.1,2 Follow-up and treatment decisions are based on a combination of clinical/laboratory/radiologic parameters and tumor size (<4 cm, 4-6 cm, >6 cm).

The 5th edition of WHO classification of adrenal cortical neoplasms introduced the term of sporadic nodular adrenocortical disease for non-functional subcentimeter benign adrenal cortical proliferations identified as incidental nodular proliferations in the adrenal gland.3,4

References

F. Primary Site and Laparoscopic Surgery

The adrenal glands sit in a supra-renal location (retroperitoneal) surrounded by connective tissue and a layer of adipose tissue. The adrenal glands are intimately associated with the kidneys and are enclosed within the renal fascia (Gerota’s). Each gland has an outer cortex, which is lipid-rich and on gross examination appears bright yellow, surrounding an inner “gray-white” medullary compartment composed of chromaffin cells. There is a rich vascular supply derived from the aorta, inferior phrenic arteries, and renal arteries. Veins emerge from the hila of the glands. The shorter right central vein opens into the inferior vena cava, and the left central vein opens into the renal vein. A single adrenal vein is present for each gland. The regional lymph nodes include the aortic lymph nodes (para-aortic, peri-aortic) and retroperitoneal lymph nodes.

An entire adrenal tumor may be removed laparoscopically, but with this technique, the gland may become fragmented. This anatomic information, including maximal diameter of the resected tumor, should be provided by the surgeon. A recent study1 demonstrates a tumor size greater than 6.5 cm is likely to be malignant in adult adrenocortical neoplasms. However, the Wieneke scoring scheme2 that is used to
assess the pediatric adrenocortical neoplasms considers a tumor size greater than 10.5 cm as a risk factor.

References

G. Weight
Accurate weights of adrenals with adrenal cortical neoplasms are important. Although tumor weight cannot be used as the sole criterion for malignancy, adrenal cortical neoplasms weighing less than 50 g are often benign, whereas the weight of malignant tumors is usually greater than 100 g in adults. Wieneke et al. reported that the mean tumor weight of pediatric adrenal cortical carcinomas was 631 g (range 24–2260 g). The Wieneke scoring system uses the adrenal cortical tumor weight greater than 400 g as a risk modifier in pediatric age groups. The weight is a reflection of the adrenal gland’s weight rather than tumor weight because, in actuality, following surgical excision, the tumor is not dissected from the gland proper and weighed separately.

References

H. Lymphatic and Vascular Invasion
The 5th edition of the WHO classification requires the distinction between lymphatic and vascular invasion, and thus, the term lymphovascular invasion is not endorsed in any endocrine neoplasm including adrenal cortical carcinomas.

According to the Weiss classification, which is typically used in the diagnostic workup of adult conventional adrenal cortical neoplasms, distinguishing between large vessel (venous) and small vessel (capillary/lymphatic) invasion may have an impact on prognosis, with large-caliber vascular space invasion portending a worse prognosis. A recent adult series also showed that microscopic angioinvasion (venous invasion) defined as tumor cells invading through a vessel wall and intravascular tumor cells admixed with thrombus proved to be the best prognostic parameter, predicting adverse outcome in all adrenal cortical carcinomas as well as within low-grade adrenal cortical carcinomas. These findings underscore the importance of the identification of angioinvasion in these neoplasms. The 5th edition of the WHO classification of adrenal cortical tumors also adopted this criterion and recognized the diagnostic and prognostic impact of vascular invasion in adrenal cortical carcinomas.

References


I. Regional Lymph Nodes
Regional lymph nodes include aortic (para-aortic and peri-aortic) and retroperitoneal (peri-nephric and peri-adrenal).

J. Staging
There are several staging systems, including those proposed by MacFarlane and modified by Sullivan et al and Henley et al and the European Network for the Study of Adrenal Tumors (ENSAT) staging scheme with the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) accepting the ENSAT as part of the TNM staging system for adrenal cortical carcinoma.°

---

*Figure 1.* T1: Tumor ≤5 cm in greatest dimension, no extra-adrenal invasion. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Manual*, 8th ed (2017) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).
Figure 2. T2: Tumor > 5 cm, no extra-adrenal invasion. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 8th ed (2016) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).

Figure 3. T3: Tumor of any size with local invasion, but not invading adjacent organs. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 8th ed (2017) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).
References


K. Metastatic Sites

Common metastatic sites include liver, lung, and retroperitoneum. Metastases to brain and skin are uncommon, although cutaneous involvement of the scalp can simulate angiosarcoma.¹

References


L. Ancillary Studies

Special procedures may include frozen sections, cytologic imprints, immunohistochemical stains, histochemical stains, electron microscopy, flow cytometry, molecular studies, and cytogenetic studies. For non-functional tumors, the 5th edition of the WHO classification of adrenal cortical tumors requires the
confirmation of the adrenal cortical origin by using appropriate biomarkers.\textsuperscript{1,2,3} SF1 stands out as the most reliable biomarker in the confirmation of adrenal cortical origin.\textsuperscript{1,2,3} The use of non-specific biomarkers of cortical differentiation (e.g., Melan-A, calretinin, synaptophysin and alpha-inhibin) is discouraged but they may be considered in a panel approach.\textsuperscript{1,2,3} Similar to synaptophysin, alpha-inhibin can be expressed in pheochromocytomas; therefore, alpha-inhibin is not a reliable biomarker of cortical differentiation.\textsuperscript{2,3,4}

Accurate assessment of Ki-67 labeling index is of clinical significance in all age groups.\textsuperscript{1,2,3,5,6,7} As per the WHO/IARC requirements, Ki-67 labeling index should be performed manually or via image analysis\textsuperscript{1,2,3,6,7,8,9}; if the latter, specifying methodology, software, or technique is suggested. Mismatch repair proteins may be tested, as adrenal cortical carcinoma is recognized in approximately 3% of Lynch syndrome patients.\textsuperscript{10,11} The demonstration of abnormal p53 (loss or overexpression) and/or diffuse nuclear beta-catenin may help in the distinction of biologically aggressive forms of adrenal cortical carcinomas.\textsuperscript{1,2,3} Therefore, it is desirable to perform p53 and beta-catenin immunohistochemistry in all adrenal cortical carcinomas.\textsuperscript{1,2,3,12} The demonstration of abnormal Ki-67 labeling index is of clinical significance in all age groups.\textsuperscript{1,2,3,5,6,7} As per the WHO/IARC requirements, Ki-67 labeling index should be performed manually or via image analysis\textsuperscript{1,2,3,6,7,8,9}; if the latter, specifying methodology, software, or technique is suggested. Mismatch repair proteins may be tested, as adrenal cortical carcinoma is recognized in approximately 3% of Lynch syndrome patients.\textsuperscript{10,11} The demonstration of abnormal p53 (loss or overexpression) and/or diffuse nuclear beta-catenin may help in the distinction of biologically aggressive forms of adrenal cortical carcinomas.\textsuperscript{1,2,3} Therefore, it is desirable to perform p53 and beta-catenin immunohistochemistry in all adrenal cortical carcinomas.\textsuperscript{1,2,3,12} The demonstration of abnormal Ki-67 labeling index is of clinical significance in all age groups.\textsuperscript{1,2,3,5,6,7} As per the WHO/IARC requirements, Ki-67 labeling index should be performed manually or via image analysis\textsuperscript{1,2,3,6,7,8,9}; if the latter, specifying methodology, software, or technique is suggested. Mismatch repair proteins may be tested, as adrenal cortical carcinoma is recognized in approximately 3% of Lynch syndrome patients.\textsuperscript{10,11} The demonstration of abnormal p53 (loss or overexpression) and/or diffuse nuclear beta-catenin may help in the distinction of biologically aggressive forms of adrenal cortical carcinomas.\textsuperscript{1,2,3} Therefore, it is desirable to perform p53 and beta-catenin immunohistochemistry in all adrenal cortical carcinomas.\textsuperscript{1,2,3,12} The demonstration of abnormal Ki-67 labeling index is of clinical significance in all age groups.\textsuperscript{1,2,3,5,6,7} As per the WHO/IARC requirements, Ki-67 labeling index should be performed manually or via image analysis\textsuperscript{1,2,3,6,7,8,9}; if the latter, specifying methodology, software, or technique is suggested. Mismatch repair proteins may be tested, as adrenal cortical carcinoma is recognized in approximately 3% of Lynch syndrome patients.\textsuperscript{10,11} The demonstration of abnormal p53 (loss or overexpression) and/or diffuse nuclear beta-catenin may help in the distinction of biologically aggressive forms of adrenal cortical carcinomas.\textsuperscript{1,2,3} Therefore, it is desirable to perform p53 and beta-catenin immunohistochemistry in all adrenal cortical carcinomas.\textsuperscript{1,2,3,12} Similar to synaptophysin, alpha-inhibin can be expressed in pheochromocytomas; therefore, alpha-inhibin is not a reliable biomarker of cortical differentiation.\textsuperscript{2,3,4}

References